BRAF and melanoma: Given the promising clinical outcomes observed with BRAF inhibitor (BRAFi) therapy in BRAF-mutated melanoma, we directed our initial focus to the dose–response profiles associated with inhibitor compounds targeting the BRAF kinase within the ERK/MAPK pathway.